tlr-3

Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5).

TLR3-IN-1 (CU CPT 4a) is a selective TLR3 inhibitor (IC50: 3.44 μM in RAW 264.7 cells). It can inhibit TLR3/dsRNA complex-mediated downstream signaling pathways and inhibit the production of TNF-α and IL-1β in whole cells.

CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).

Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic double-stranded RNA (dsRNA) analog and an agonist of TLR3 as well as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5). It can induce innate immune responses in mammals and serve as a vaccine adjuvant to enhance both innate and adaptive immunity, while modulating the tumor microenvironment and directly inducing apoptosis in cancer cells. Poly(I:C) is commonly used to establish acute respiratory distress syndrome (ARDS) animal models for studying immune responses and disease mechanisms.

Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO-expressed human antibody designed to target TLR3/CD283. It features a huIgG2 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145.42 kDa. For its isotype control, refer to HumanIgG4kappa, Isotype Control.

TLR7/8 agonist 3 is a potent activator of TLR7 and TLR8.

ODN 1668 sodium is a B class CpG ODN (oligodeoxynucleotide) recognized as a TLR-9 agonist. It demonstrates potent immunomodulatory effects by enhancing the level of IgG2 subtype antibodies and stimulating both T cell and B cell immune responses, making it useful for vaccine adjuvant research. Additionally, CpG ODN 1668 sodium induces antibacterial immune responses in orange-spotted grouper through a CaTLR9-dependent pathway. Sequence: 5’-tccatgacgttcctgatgct-3’.

Givinostat (ITF-2357) is an HDAC inhibitor with IC50 values of 198 nM for HDAC1 and 157 nM for HDAC3.

Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases. Polygalasaponin F can significantly i

TLR7 agonist 3 is a Toll-like receptor 7 (TLR7) agonist that has anticancer activity and is used in the study of diseases of the immune system.

Lipopolysaccharides from Escherichia coli O111:B4 are key components of the outer membrane of Gram-negative bacteria. As a smooth-type LPS, they consist of lipid A, an R3-type core oligosaccharide, and an O-specific polysaccharide. These LPS molecules exhibit high immunogenicity, can trigger strong immune responses and gastric disorders by activating the TLR-4 receptor on immune cells, and help maintain the structural integrity of the bacterial outer membrane while protecting against bile salts and lipid-based antibiotics. They are widely used to establish inflammation-related disease models, such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS).

Sophocarpine, a major ingredient of Sophora alopecuroides, has a wide range of pharmacological effects.

1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possib

ODN 1018 (1018 ISS) is a synthetic oligodeoxynucleotide that functions as a Toll-like receptor 9 (TLR-9) agonist and immunostimulatory sequence, with the defined sequence 5′-TGACTGTGAACGTTCGAGATGA-3′, ODN 1018 is widely applied as a vaccine adjuvant and immunology research tool to activate innate immune responses and enhance antigen-specific immunity.

ODN 2007 sodium is a class B CpG oligodeoxynucleotide that functions as a Toll-like receptor ligand, robustly activating innate immune signaling pathways and serving as an effective immunomodulator and vaccine adjuvant, with demonstrated capacity to enhance immune responses across mammals, fish, and humans, and defined by the sequence 5'-TCGTCGTTGTCGTTTTGTCGTT-3' for reproducible immunological studies.

Ginsenoside Rg5 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg5. 1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.